# US 10,479,988 B2 · Method of making a vaccine

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,479,988 B2
- Document ID: US10479988B2
- Status: Granted
- Kind: B2
- Application number: 15/720,336
- Filed: 2017-09-29
- Published: 2019-04-04
- Granted: 2019-11-19
- Earliest claimed: 2017-09-29
- Assignees: Lumagenics, LLC
- Applicants: Hyper Light Technologies, LLC
- Inventors: Kurt A. Garrett
- Web page: https://patentgrep.com/patent/US10479988B2

## CPC

- C12N 13/00: Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- C12N 1/36: Adaptation or attenuation of cells
- A61K 2039/522: {avirulent or attenuated}
- A61K 2039/5254: {avirulent or attenuated}
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A method of producing attenuated cells for a mammalian vaccine comprising killing or attenuating the cells with a high energy, low heat UV light.

## Claims

### Claim 1

A method of producing a live or dead attenuated infectious cells comprising:
a) isolating a plurality of infectious cells;
b) selecting a high energy UV light source that delivers a low heat UV containing light to the end of a light guide;
c) selecting the UV light source and output so that UV energy from the light source can selectively attenuate cells; and
d) exposing the infectious cells to the light from the end of the light guide at sufficient distance and wherein the cells are exposed to the light from about 0.1 seconds to about 5 seconds to attenuate the cells without damaging cellular proteins and carbohydrates that produce the immune response to produce attenuated cells.

### Claim 2 (depends on 1)

The method according to claim 1 wherein the attenuated cells are formulated into a vaccine.

### Claim 3 (depends on 2)

The method according to claim 2 wherein the vaccine is administered to a mammal in a dose effective to elicit an immune response that creates antibodies to the infectious cells.

### Claim 4

A method of producing a live or dead attenuated infectious cells comprising:
a) isolating a plurality of infectious cells;
b) selecting a high energy UV light source having an output of at least about 80 lumens per watt that delivers a low heat UV containing light to the end of a light guide;
c) selecting the UV light source and output so that UV energy from the light source can selectively attenuate cells; and
d) exposing the infectious cells to the light from the end of the light guide at sufficient distance and time to attenuate the cells without damaging cellular proteins and carbohydrates that produce the immune response to produce attenuated cells.

### Claim 5 (depends on 4)

The method according to claim 4 wherein the attenuated cells are formulated into a vaccine.

### Claim 6 (depends on 5)

The method according to claim 5 wherein the vaccine is administered to a mammal in a dose effective to elicit an immune response that creates antibodies to the infectious cells.

### Claim 7 (depends on 1)

The method according to claim 1 wherein the cells are exposed to the light from about 0.1 seconds to about 5 seconds.